Eli Lilly announced its acquisition of Centessa Pharmaceuticals for up to $7.8 billion, while Biogen separately revealed plans to acquire Apellis Pharmaceuticals for up to $6.1 billion in two significant biotech deals.
Biogen's acquisition of Apellis will expand its portfolio with Empaveli (pegcetacoplan), an approved therapy for rare kidney diseases including C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN), as well as paroxysmal nocturnal hemoglobinuria (PNH) in adult patients.